Gilead Sciences Inc. (NASDAQ:GILD) shares traded -2.06% lower at $78.00 on Wall Street last session.
In accordance with the data, 30 analysts cover Gilead Sciences Inc. (NASDAQ:GILD). The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $116.00 and a low of $80.00, we find $90.00. Given the previous closing price of $79.64, this indicates a potential upside of 13.01 percent. GILD stock price is now 0.49% away from the 50-day moving average and -4.21% away from the 200-day moving average. The market capitalization of the company currently stands at $97.19B.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
It has been rated a hold by 16 analysts and a buy by 13. Brokers who have rated the stock have averaged $91.23 as their price target over the next twelve months.
With the price target reduced from $81 to $80, Barclays maintained Equal Weight rating for Gilead Sciences Inc. (NASDAQ: GILD).
In other news, Dickinson Andrew D, Chief Financial Officer sold 5,000 shares of the company’s stock on Jul 20. The stock was sold for $400,000 at an average price of $80.00. Upon completion of the transaction, the Chief Financial Officer now directly owns 107,587 shares in the company, valued at $8.39 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Jun 28, 10% Owner GILEAD SCIENCES, INC. bought 1,010,000 shares of the business’s stock. A total of $19,452,600 was incurred on buying the stock at an average price of $19.26. This leaves the insider owning 14,823,029 shares of the company worth $1.16 billion. Insiders disposed of 230,852 shares of company stock worth roughly $18.01 million over the past 1 year. A total of 0.10% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in GILD stock. A new stake in Gilead Sciences Inc. shares was purchased by PORTSIDE WEALTH GROUP, LLC during the first quarter worth $28,298,000. UNISUPER MANAGEMENT PTY LTD invested $24,507,000 in shares of GILD during the first quarter. In the first quarter, TWINBEECH CAPITAL LP acquired a new stake in Gilead Sciences Inc. valued at approximately $21,884,000. EXODUSPOINT CAPITAL MANAGEMENT, LP acquired a new stake in GILD for approximately $21,784,000. GENUS CAPITAL MANAGEMENT INC. purchased a new stake in GILD valued at around $11,832,000 in the second quarter. In total, there are 2,350 active investors with 83.00% ownership of the company’s stock.
Gilead Sciences Inc. (NASDAQ: GILD) opened at $79.12 on Wednesday. During the past 12 months, Gilead Sciences Inc. has had a low of $61.44 and a high of $89.74. As of last week, the company has a debt-to-equity ratio of 1.19, a current ratio of 1.00, and a quick ratio of 0.90. According to the stock market information, the enterprise value for the company is $117.81B, which is based on a 17.94 price-to-earnings ratio, a 5.88 price-to-earnings-growth ratio, and a beta of 0.37. The fifty day moving average price for GILD is $77.62 and a two-hundred day moving average price translates $81.46 for the stock.
The latest earnings results from Gilead Sciences Inc. (NASDAQ: GILD) was released for Jun, 2023. According to the Drug Manufacturers – General Company, earnings per share came in at $1.34, missing analysts’ expectations of $1.64 by -0.3. This compares to $0.90 EPS in the same period last year. The net profit margin was 20.00% and return on equity was 26.00% for GILD. The company reported revenue of $6.6 billion for the quarter, compared to $6.26 billion a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 5.42 percent. For the current quarter, analysts expect GILD to generate $6.81B in revenue.
Moreover, the firm recently paid out its quarterly dividend on 09/28/2023. Investors who held shares on 09/15/2023 were paid a $0.75 dividend. On an annualized basis, this represents a $3.00 dividend and a 3.85% percent yield. There was an ex-dividend date of 09/14/2023 for this dividend. In terms of dividend payout ratio, GILD is presently at 67.60%.
Gilead Sciences Inc.(GILD) Company Profile
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Merck & Co, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.
